Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
APOL now on LSE....see you over there.
All go, rns out, 8am kickoff
Going forward, the company is looking at potential “third-party sales agreements” for Apollon products in countries such as South Africa and Greece, says Jacobs.
Corporate developments may include ‘up listing’ here in the UK and taking a stock market quote in the US, most likely on the OTC QB.
Jacobs says the company has news flow “coming thick and fast” after the RTO.
Formulations are, and will continue to be, patented.
https://www.apollon.org.uk/operations/medically-supervised-trials
Exclusivity on some of Docs patents hopefully.....................
Is it calculating 780 million shares to market cap of £65 million so 8.3 pence per share, close to now? Be interesting
Don’t get it, see the enlarged number shares, read the change in market cap but no idea how this translates into an sp and allocation of shares to me as an example, how many will I have at what price?
Maybe the Doc in the background????????????
https://www.youtube.com/watch?v=n3LJatp1slk
5 views only....................
https://www.youtube.com/watch?v=p-mVzWbar9U
Market Cap: £65,482,959
Info.................. BOD needs updating twitter link still for AfriAG
https://www.aquis.eu/aquis-stock-exchange/companies-and-prices
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=APOL
ETAILS OF ANY LOCK-IN ARRANGEMENTS:
A lock-in agreement was executed by and among the Company, the Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree and Peterhouse, pursuant to which the Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree have undertaken, save in certain circumstances, not to sell or
otherwise dispose of or agree to sell or dispose of any of their interests (direct or indirect) in the Ordinary
Shares held by them (or subsequently acquired by them) for a period of twelve months commencing on the
date of Admission (“Lock-in Period”). In addition, the Proposed Directors, Apollon Formularies, Inc. and
Roderick McIllree have undertaken to the Company and Peterhouse not to dispose of their Ordinary Shares
for a period of 12 months after the end of the Lock-in Period without first consulting the Company and
Peterhouse in order to maintain an orderly market for the Ordinary Shares. The Proposed Directors, Apollon
Formularies, Inc. and Roderick McIllree will hold in aggregate 413,483,412 Ordinary Shares representing
55.25 per cent. of the Enlarged Share Capital, on Admission.
AQUIS REGULATORY APPROVAL TO ACQUIRE APOLLON
The Company is pleased to announce that at the General Meeting of the Company held today, all resolutions were duly passed. The Company is also pleased to announce that AQSE Regulatory approval to be admitted to the AQSE Growth Market has now been received to acquire the entire issued share capital of Apollon Formularies Limited, and it is expected that admission to trading will commence tomorrow, 13 April 2021 at 8 a.m. The Enlarged Share Capital of 748,376,677 Ordinary Shares will be admitted to trading, comprising 31,710,011 Existing Ordinary Shares, 666,666,666 Consideration Shares and 50,000,000 Placing Shares and Subscription Shares.
https://www.aquis.eu/aquis-stock-exchange/for-investors/announcements?view_news_id=3042910
Apollon Formularies
@apollon_uk
·
56m
RESULT OF GM AND AQUIS REGULATORY APPROVAL TO ACQUIRE APOLLON
The Company is also pleased to announce that AQSE Regulatory approval to be admitted to the AQSE Growth Market
Apollon Formularies admission to trading will commence 13 April 2021 at 8 a.m
https://twitter.com/apollon_uk
Withdrawn....................
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=AFRI
Who ?
in the "not too distant future"
Lenigas & team no longer in charge either.
We will have new buyers, and maybe stock bashers.................
Bashers only bash good shares.....
another opportunity for the Lenigas machine to turn investors cash into his cash ...
Apollon Formularies
@apollon_uk
·
10m
“We are delighted to be coming to market at such an important time for #medicalcannabis across the UK."
General Meeting at 10a.m. today.
Expected Admission 13th April 2021 subject to Shareholder and regulatory approval.